Design, synthesis, and biological evaluation of novel 1-aryl-3-hydroxypyrrolidine derivatives as dual HGK/HPK1 inhibitors with therapeutic potential for lung cancer
Bioorganic Chemistry · 2026
DOI: 10.1016/j.bioorg.2026.110473 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Shuyu Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Drug Design, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit nennt 26 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Recent research certified that HGK, as an upstream regulator of the MAPK/ERK signaling pathway, represents a promising target for lung cancer therapy. Herein, in pursuit of novel HGK inhibitors, a series of 1-aryl-3-hydroxypyrrolidine derivatives were designed and synthesized based on the hit compound Z1, which was obtained via high-throughput screening. Through comprehensive biological evaluation, Z7 was identified as the optimal compound with potent enzymatic (HGK IC50 = 0.047 μM) and cellular activities (H460 IC50 = 1.42 μM). Notably, Z7 also demonstrated marked inhibition against HPK1 (IC50 = 0.065 μM) in selectivity assessment, positioning it as a dual HGK/HPK1 inhibitor. Moreover, Z7 exhibited favorable selectivity across a panel of 80 kinases and pronounced in vivo anti-lung cancer efficacy (TGI = 68.94% at 20 mg/kg dosage) in H460 xenograft models. Overall, our findings suggest that dual targeting of HGK and HPK1 represents a viable therapeutic strategy for lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
- School of Pharmacy, Shenyang Medical College, Shenyang 110034, China.
- School of Pharmacy, Shenyang Medical College, Shenyang 110034, China. Electronic address: ladycainan@126.com.
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: tanzehui_syphu@163.com.
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: zhaixin_syphu@126.com.
Förderung
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Liu, S., Ma, J., Li, Y., Yang, J., Zhang, D., Cai, N., Tan, Z., & Zhai, X. (2026). Design, synthesis, and biological evaluation of novel 1-aryl-3-hydroxypyrrolidine derivatives as dual HGK/HPK1 inhibitors with therapeutic potential for lung cancer. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.110473
Vancouver
Liu S, Ma J, Li Y, Yang J, Zhang D, Cai N, et al. Design, synthesis, and biological evaluation of novel 1-aryl-3-hydroxypyrrolidine derivatives as dual HGK/HPK1 inhibitors with therapeutic potential for lung cancer. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.110473
BibTeX
@article{Liu2026,
author = {Liu, Shuyu and Ma, Jiajun and Li, You and Yang, Junyi and Zhang, Dajun and Cai, Nan and Tan, Zehui and Zhai, Xin},
title = {Design, synthesis, and biological evaluation of novel 1-aryl-3-hydroxypyrrolidine derivatives as dual HGK/HPK1 inhibitors with therapeutic potential for lung cancer},
journal = {Bioorganic Chemistry},
year = {2026},
doi = {10.1016/j.bioorg.2026.110473}
}
EUVIMED